Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:34:55 2025-01-21 am EST			5-day change	1st Jan Change
565.40 ^DKK	+2.56%		-5.22%	-10.06%

Jan. 03	New Year, Soft Start
Jan. 03	BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform	MT

Press Releases

Novo Nordisk A/S, Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence	Jan. 20	AQ
Novo Nordisk A/S - share repurchase programme	Jan. 20	GL
Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations	Jan. 17	AQ
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence	Jan. 17	GL
Novo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD	Jan. 13	AQ
Novo Nordisk A/S - share repurchase programme	Jan. 13	GL
University of Bath: Researchers call for legislative reform to improve transparency in drug company payments	Jan. 10	AQ
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases	Jan. 08	GL
Novo Nordisk A/S, CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial	Dec. 23	AQ
Stock market today: Wall Street leaps and halves its losses from what had been a dismal week	Dec. 20	AQ
Stock market today: Wall Street rallies to trim its losses from a rough week	Dec. 20	AQ
Novo Nordisk A/S : Share repurchase programme Form 6 K	Dec. 20	PU
Novo Nordisk A/S : CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial Form 6 K	Dec. 20	PU
Novo Nordisk A/S - share repurchase programme	Dec. 20	GL
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial	Dec. 20	GL
Novo Nordisk A/S : The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed Form 6 K	Dec. 18	PU
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed	Dec. 18	GL
Novo Nordisk A/S, The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close	Dec. 16	AQ
Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction	Dec. 16	AQ
Novo Nordisk A/S : Share repurchase programme Form 6 K	Dec. 16	PU
Novo Nordisk A/S : The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close Form 6 K	Dec. 16	PU
Novo Nordisk A/S - share repurchase programme	Dec. 16	GL
Novo Nordisk investing in rare disease with major new manufacturing site	Dec. 16	AQ
Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark	Dec. 16	GL
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close	Dec. 14	AQ

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Wegovy, Ozempic Targeted by US for Medicare Price Cuts

January 17, 2025 at 10:36 am EST

Cagrisema sends Novo Nordisk to the mat

December 20, 2024 at 06:20 am EST

NOVO NORDISK : CagriSema results are not worthy of panic

December 20, 2024 at 09:14 am EST